• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    XOMA Royalty Corporation - Common Stock (NQ:XOMA)

    41.37 -0.23 (-0.55%)
    Streaming Delayed Price Updated: 1:56 PM EDT, May 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about XOMA Royalty Corporation - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    Halper Sadeh LLC is Investigating Whether HLX, OGN, XOMA, RMAX are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC is Investigating Whether SLNO, OGN, RMAX, XOMA are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC is Investigating Whether XOMA, RMAX, GRTX are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    XOMA Royalty Corporation (NASDAQ:XOMA) Passes Key Growth and Momentum Filters ↗
    Via Chartmill
    XOMA Royalty Corporation (NASDAQ:XOMA) Passes Strict "Little Book" Growth Stock Screen ↗
    Via Chartmill
    XOMA Royalty Corporation (NASDAQ:XOMA) Beats Q4 2025 Earnings Estimates, Stock Rises ↗
    Via Chartmill
    News headline image
    XOMA Investors Have the Opportunity to Join Investigation of XOMA Royalty Corporation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Declares Quarterly Preferred Stock Dividends
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Jumps After Q4 Double Beat, Signals Pipeline Catalysts Ahead ↗
    XOMA Royalty Corporation (NASDAQ: XOMA) shares are trading higher Wednesday after the company reported fourth-quarter financial results. 
    Via Benzinga
    News headline image
    XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data ↗
    Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway. 
    Via The Motley Fool
    Topics Stocks
    News headline image
    XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty to Present at Investor Conferences in March
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
    Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right 
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    XOMA Royalty Announces CFO Transition
    From XOMA Royalty Corporation
    Via GlobeNewswire
    Unusual volume stocks in Wednesday's session ↗
    Via Chartmill
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Declares Quarterly Preferred Stock Dividends
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Enters into Agreement to Acquire Generation Bio
    From Generation Bio Co.; XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    XOMA Royalty Corporation: A Deep Dive into a Biotech Royalty Aggregator (12/13/2025)
    XOMA Corporation (Nasdaq: XOMA), operating as XOMA Royalty Corporation since July 2024, has undergone a profound strategic metamorphosis, transitioning from a traditional biopharmaceutical developer to... 
    Via PredictStreet
    Topics Intellectual Property
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.